Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | TCR redirected T cells for cancer therapy

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes her research presented at the International Conference on Lymphocyte Engineering (ICLE) on multiple genome editing in T cells for cancer immunotherapy. Dr Bonini describes a strategy under investigation for the potential treatment of acute myeloid leukemia (AML), which involves the knockout of two genes encoding the alpha-beta chain of the endogenous T cell receptor (TCR) in lymphocytes, followed by substitution with a tumor-specific TCR that recognizes cancer cells. Ongoing research is being performed to evaluate similar approaches in other types of cancer. This interview took place at ICLE 2022.